Sulfamethoxazole And Trimethoprim

Introduction Overview

Generic Name

sulfamethoxazole and trimethoprim

Brand Name

Bactrim
Bactrim DS
Sulfatrim Pediatric
Septra
Sulfatrim
Bethaprim
Cotrim
Uroplus
Uroplus DS
Cotrim DS
Septra I.V.
Bactrim I.V.
Bactrim Pediatric
Bethaprim Pediatric
Sulfatrim Suspension
Cotrim Pediatric
Septra DS
SMZ-TMP DS

Dosage Form

intravenous solution
oral suspension
oral tablet

Drug Class

Sulfonamides

Pharmacokinetics

Absorption:
Sulfamethoxazole and trimethoprim are rapidly and well absorbed following oral administration, with sulfamethoxazole absorbed mainly from the stomach and upper small intestine and trimethoprim absorbed throughout the gastrointestinal tract. Oral bioavailability is high, often exceeding 85%, facilitating effective systemic drug concentrations. Food intake may delay absorption but does not significantly reduce bioavailability. The combination allows for synergistic antimicrobial activity with effective plasma levels maintained for dosing intervals.

Distribution:
After absorption, both drugs are widely distributed throughout the body tissues and fluids. Trimethoprim exhibits a large volume of distribution as it penetrates well into tissues, including the lungs, kidneys, and cerebrospinal fluid (CSF), making it effective in treating systemic and intracellular infections. Sulfamethoxazole also distributes extensively but achieves lower concentrations in CSF compared to trimethoprim. Both drugs bind moderately to plasma proteins (approximately 70% for sulfamethoxazole and 44% for trimethoprim), influencing their free active concentrations.

Metabolism:
Sulfamethoxazole undergoes hepatic metabolism primarily via hydroxylation and glucuronidation pathways mediated by cytochrome P450 enzymes, with metabolites excreted renally. Trimethoprim is partially metabolized hepatically through demethylation, but its metabolism is less extensive. Both parent compounds and metabolites contribute to antimicrobial activity and toxicity profiles. Hepatic impairment can alter metabolism and increase plasma drug levels, requiring dose adjustments.

Elimination:
Both sulfamethoxazole and trimethoprim are primarily excreted by the kidneys via glomerular filtration and tubular secretion. The elimination half-life of sulfamethoxazole ranges from 10 to 12 hours, and trimethoprim ranges from 8 to 10 hours in patients with normal renal function, supporting twice-daily dosing regimens. In renal impairment, drug clearance decreases, leading to increased plasma levels and prolonged half-life, necessitating dose modification to avoid toxicity. Both drugs are also partially removed by hemodialysis. The combination is effectively cleared in patients with normal renal and hepatic function, ensuring efficacy and safety when dosed appropriately.

Dosage Forms

Available Dosage Forms:
- Intravenous solution: 80 mg sulfamethoxazole and 16 mg trimethoprim per mL
- Oral suspension (liquid): 200 mg sulfamethoxazole and 40 mg trimethoprim per 5 mL
- Oral tablets:
- 400 mg sulfamethoxazole and 80 mg trimethoprim
- 800 mg sulfamethoxazole and 160 mg trimethoprim (Double Strength)

Dosages for Adults and Adolescents:
Treatment regimens vary according to indication but generally, adults and adolescents receive:
- For urinary tract infections, bronchitis, or ear infections: 1 double-strength tablet (800 mg/160 mg) every 12 hours for 10 to 14 days
- For Pneumocystis jiroveci pneumonia (PCP) prophylaxis and treatment: higher dosing with frequent monitoring may be required
- The oral suspension is utilized in patients who have difficulty swallowing tablets, with dosing calculated by mg/kg body weight
- Intravenous formulation is reserved for patients unable to take oral medications or requiring hospitalization, dosed accordingly by weight and indication

Specific Patient Populations:
- Pediatric patients older than 2 months may receive dosing adjusted by weight, with pediatric-specific formulations such as Sulfatrim Pediatric available
- Sulfamethoxazole and trimethoprim is contraindicated in neonates under 2 months due to risk of kernicterus
- Dose adjustments are mandatory for patients with renal impairment to prevent accumulation and toxicity
- Pregnant women are generally advised not to use the drug due to potential teratogenic effects; safety during breastfeeding is also contraindicated
- Patients with hepatic dysfunction require cautious dosing and monitoring

Clinicians should follow detailed dosage guidelines according to the infection type, severity, and patient-specific factors to optimize therapeutic outcomes while minimizing adverse effects.

Mechanism Of Action

Sulfamethoxazole and trimethoprim act synergistically to inhibit sequential steps in the bacterial folic acid synthesis pathway, crucial for DNA and RNA synthesis in susceptible microorganisms. Sulfamethoxazole, a sulfonamide antibiotic, competitively inhibits dihydropteroate synthase, blocking the incorporation of para-aminobenzoic acid (PABA) into dihydropteroic acid, an early step in tetrahydrofolate synthesis. This impairs the production of folate derivatives necessary for microbial replication.

Trimethoprim, a diaminopyrimidine antibiotic, inhibits dihydrofolate reductase (DHFR), an enzyme downstream in the folate pathway responsible for converting dihydrofolate to tetrahydrofolate. This leads to depletion of reduced folate pools, critical cofactors for nucleotide biosynthesis, and DNA replication. By inhibiting two enzymes in sequence, the combination acts synergistically to produce a bactericidal effect that exceeds the sum of their individual actions.

This dual blockade enhances antimicrobial efficacy, broadens the spectrum against gram-positive and gram-negative bacteria, and reduces the likelihood of resistance development. The selective inhibition is effective against many clinically important pathogens such as Escherichia coli, Klebsiella species, and Pneumocystis jiroveci. Notably, this mechanism spares human cells as mammals acquire folate through diet rather than de novo synthesis.

Clinical studies have demonstrated the combination's effectiveness in treating urinary tract infections, respiratory infections, gastrointestinal infections, and certain opportunistic infections such as Pneumocystis jiroveci pneumonia. Its bactericidal activity and oral bioavailability make it a mainstay in antimicrobial therapy, with pharmacological properties supporting dosing schedules that maintain effective plasma concentrations. Comparative research with other antibiotics has shown that the combination holds valuable clinical utility, particularly in multi-drug resistant infections.

Pharmacological Actions

Bactericidal activity through sequential inhibition of folic acid synthesis enzymes (dihydropteroate synthase and dihydrofolate reductase).
Synergistic antimicrobial effect enhancing potency compared to individual agents.
Broad spectrum efficacy against gram-positive and gram-negative bacteria.
Effective in treatment and prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients.
Inhibits bacterial DNA, RNA, and protein synthesis leading to bacterial cell death.
Good penetration into body fluids including urine, sputum, and cerebrospinal fluid.
Moderate binding to plasma proteins enabling effective tissue distribution.
Supports oral and intravenous administration for versatile clinical use.
Acts selectively on bacterial enzymes without affecting human folate metabolism.
Useful in treating respiratory tract infections, urinary tract infections, gastrointestinal infections, and certain skin infections.
Reduces bacterial resistance development due to dual target inhibition.
Can modulate immune response in some infectious conditions by reducing bacterial load.
Exhibits favorable pharmacokinetics allowing twice-daily dosing schedules.
Useful in patients with sulfa-sensitive infections when desensitization is possible.

Therapeutic Or Clinical Uses

Treatment of urinary tract infections including cystitis and pyelonephritis.
Management of acute and chronic bronchitis caused by susceptible bacteria.
Therapy for otitis media and other ear infections.
Treatment of traveler’s diarrhea caused by enteric pathogens including Shigella.
Prophylaxis and treatment of Pneumocystis jiroveci pneumonia, especially in HIV/AIDS patients.
Management of shigellosis and other gastrointestinal infections.
Treatment of certain skin and soft tissue bacterial infections.
Used for treatment of diverticulitis in combination with other agents.
Alternative treatment for nocardiosis in susceptible patients.
Utilized in immunocompromised patients to prevent opportunistic infections.
Empiric therapy for febrile neutropenia in combination with other antibiotics.
Treatment of MRSA infections in selected cases resistant to other therapies.
Used in some cases of toxoplasmosis adjunctively.
Management of infections caused by susceptible strains of Staphylococcus aureus and Streptococcus species.
Applied in veterinary medicine as an antibacterial agent for certain infections.

Side Or Adverse Effects

Hypersensitivity reactions including rash, pruritus, urticaria, and rarely Stevens-Johnson syndrome or toxic epidermal necrolysis.
Gastrointestinal disturbances such as nausea, vomiting, anorexia, and diarrhea.
Hematologic abnormalities including agranulocytosis, aplastic anemia, thrombocytopenia, and leukopenia.
Photosensitivity leading to increased risk of sunburn upon light exposure.
Hyperkalemia manifesting as nausea, muscle weakness, cardiac arrhythmias.
Hyponatremia with neurological symptoms including headache, confusion, and seizures.
Renal toxicity including crystalluria and interstitial nephritis; adequate hydration recommended.
Elevated liver enzymes and rare instances of hepatic necrosis.
Central nervous system effects such as headache, dizziness, and rarely aseptic meningitis.
Allergic reactions with respiratory symptoms including cough and bronchospasm.
Potential blood dyscrasias presenting with easy bruising, bleeding, or pallor.
Elevated blood glucose changes including hypoglycemia in rare cases.
Possible seizures particularly in patients with renal impairment or electrolyte abnormalities.
Severe skin reactions presenting with fever, sore throat, and malaise may precede rash.
G6PD deficiency patients may experience hemolytic anemia following administration.

Precautions

Assess for sulfa drug allergy prior to initiating therapy; contraindicated in known hypersensitivity to sulfonamides or trimethoprim.
Use with caution in patients with renal impairment; dose adjustment and regular monitoring required.
Not recommended in infants under 2 months due to risk of kernicterus.
Avoid use during pregnancy due to potential risk of congenital malformations and neonatal jaundice.
Discontinue drug if severe skin rash or signs of hypersensitivity occur.
Monitor electrolyte levels periodically, especially potassium and sodium.
Caution in patients with folate deficiency or megaloblastic anemia; consider folic acid supplementation.
Use carefully in patients with hepatic dysfunction; liver function tests are advised.
Watch for signs of blood dyscrasias with periodic complete blood counts during prolonged therapy.
Advise patients to avoid excessive sun exposure, tanning beds, and use sunscreen.
Maintain adequate hydration to minimize risk of crystalluria and renal complications.
Avoid concomitant use with drugs known to increase potassium or cause bone marrow suppression without close monitoring.
Assess for potential drug-drug interactions before starting therapy.
Use cautiously in patients with glucose-6-phosphate dehydrogenase deficiency.
Pregnant and lactating women should consult healthcare providers carefully before use.

Warnings

Do not use in patients with known hypersensitivity to sulfonamides or trimethoprim.
Associated with potentially fatal severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.
May cause life-threatening blood disorders; monitor blood counts regularly.
Contraindicated in patients taking dofetilide due to risk of serious cardiac arrhythmias.
Risk of hyperkalemia which can lead to cardiac arrest; monitor serum potassium especially in susceptible patients.
Not to be administered to neonates or premature infants due to risk of kernicterus.
May cause serious infections secondary to disruption of normal flora, including Clostridium difficile-associated diarrhea.
Potential teratogenic effects and fetal harm; avoid use during pregnancy.
Injection form contains propylene glycol; avoid foods and drugs with propylene glycol concomitantly to prevent toxicity.
May exacerbate folic acid deficiency anemia and should be used cautiously in patients with low folate stores.
Avoid use in severe hepatic or renal disease without specialist supervision.
May interfere with laboratory tests including INR and prothrombin time; monitoring adjustments may be required.
Should not be used for viral infections such as flu or common cold.
Potential for severe allergic reactions necessitates immediate medical attention if symptoms arise.
Discontinue promptly if signs of hypersensitivity, hepatotoxicity, or hematologic toxicity appear.

Contraindication

Known allergy or hypersensitivity to sulfamethoxazole, trimethoprim, or other sulfonamide drugs.
Severe liver disease or hepatic impairment without proper monitoring.
Untreated or unmonitored renal disease with compromised kidney function.
Anemia caused by folic acid deficiency.
History of thrombocytopenia or low blood platelets triggered by trimethoprim or sulfa drugs.
Concurrent use of dofetilide due to risk of life-threatening arrhythmias.
Neonates aged less than 2 months due to risk of kernicterus and toxicity.
Pregnancy, especially in the first trimester and near term, because of teratogenic and neonatal risks.
Patients with documented glucose-6-phosphate dehydrogenase deficiency at risk of hemolysis.
Patients with severe hypersensitivity reactions history to similar drugs.
Concomitant use with drugs causing severe bone marrow suppression without close monitoring.
Severe electrolyte imbalances particularly hyperkalemia or hyponatremia that cannot be corrected.
Patients with porphyria as sulfonamides may precipitate an attack.
Known severe allergic asthma or anaphylaxis with sulfonamide group.
Those with a history of severe rash or drug reaction with eosinophilia and systemic symptoms related to sulfonamides.

Drug Interactions

Increased risk of hyperkalemia when used concomitantly with potassium-sparing diuretics such as spironolactone or ACE inhibitors like lisinopril.
Potentiation of anticoagulant effect of warfarin leading to increased bleeding risk; requires close monitoring of INR.
Enhanced risk of bone marrow suppression when combined with methotrexate or other folate antagonists.
May increase plasma levels and toxicity of phenytoin due to metabolic inhibition.
Concomitant use with cyclosporine can increase nephrotoxicity risk.
Trimethoprim may enhance effects of oral hypoglycemic drugs increasing risk of hypoglycemia.
Use with indomethacin can elevate plasma trimethoprim concentrations, increasing toxicity risk.
Potential reduction in efficacy of oral contraceptives when used concurrently due to gastrointestinal disturbance or altered metabolism.
Concomitant use with amantadine may increase risk of adverse effects.
Co-administration with procainamide may increase cardiac toxicity risks.
May potentiate effects of drugs metabolized by CYP450 due to sulfamethoxazole’s inhibitory effect.
Caution with other nephrotoxic agents such as aminoglycosides or amphotericin B to reduce kidney injury risk.
Concomitant use with diuretics necessitates electrolyte monitoring.
Increased risk of hyperkalemia when used with trimethoprim-containing drugs and ACE inhibitors or angiotensin receptor blockers.
May interfere with laboratory coagulation assays, necessitating monitoring adjustments during concurrent use with anticoagulants.

Preparations Of The Drug

Oral tablets containing 400 mg sulfamethoxazole and 80 mg trimethoprim (single strength).
Oral tablets containing 800 mg sulfamethoxazole and 160 mg trimethoprim (double strength).
Oral suspension with concentration of 200 mg sulfamethoxazole and 40 mg trimethoprim per 5 mL, for pediatric and liquid formulation needs.
Intravenous solution with concentration of 80 mg sulfamethoxazole and 16 mg trimethoprim per mL, for parenteral use especially in hospitalized patients.
Pediatric-specific formulations such as Sulfatrim Pediatric suspensions designed for infant and child dosing.
Concentrated injectable formulations necessitating proper dilution before administration and having limited stability post-mixing.
Combination products marketed under various brand names including Bactrim, Septra, SMZ-TMP DS, and others for distinct clinical uses.
Suspension and injectable forms require careful handling and storage conditions, including avoidance of refrigeration in mixed preparations.
Tablet formulations designed to optimize bioavailability and patient compliance through twice-daily dosing regimens.
Various strengths and formulations available to allow dose tailoring for specific infections and patient populations.
Preparations supplied with appropriate dosing devices to ensure accurate oral suspension administration.
Intravenous formulations intended for use in severe infections or when oral administration is not feasible.
Generic and branded versions available worldwide, ensuring accessibility and cost-effectiveness.
Each preparation requires adherence to storage guidelines to maintain potency and reduce degradation.